The government stated that the reclassification of cannabis to class C had the desired effect (with arrests for cannabis possession falling by one third in the first year following), saving an estimated 199,000 police hours. The transfer eventually happened in January 2004 — after class C penalties for distribution had been stiffened. Although the number of cannabis-based medications prescribed by the NHS still remains extremely low in relation to the other conventional medicines, and low in relation to the number of private prescriptions issued, it appears relations with the NHS are slowly moving in the right direction. Currently, only doctors included on the General Medical Council’s Specialist Register can prescribe these products in the UK, and only about 100 are estimated to do so – which is approximately 0.25% of those that can. In the last year, the subject of medical cannabis has been included in parliamentary discussions on a number of occasions.
But many feel policy change is inevitable, especially given European countries including Malta, Luxembourg, Czechia, Switzerland, the Netherlands and Germany are all moving towards regulation. Our next step is to introduce strains that we think people will like — but don’t necessarily know to exist, because it’s difficult to grow so you don’t find it on the illegal markets— exotic flavor profiles. Report (Cannamonitor estimates that 79% of these prescriptions are for flower), with many high in THC and almost all imported from overseas. Dalgety is the first company to obtain an EU-GMP license for the cultivation, manufacture and supply of a medical cannabis flower API from the MHRA.
Over **5,000 UK patients** currently rely on privately funded CBMP prescriptions for conditions like chronic pain (anxiety), PTSD, insomnia, and treatment-resistant epilepsy. Patients are forced to either pay **hundreds of pounds monthly** for private prescriptions or obtain cannabis **illegally**, bypassing regulated channels. Since legalisation (**fewer than 5,000 NHS cannabis prescriptions** have been issued—despite **around 1.4 million UK patients** using it medicinally), mostly from **unlicensed sources or private clinics**. Specialist physicians have been legally authorised to prescribe CBMPs since **1 November 2018** (yet **only a handful of NHS prescriptions** have been dispensed), forcing most patients to **self-fund privately at high cost**. After five years (the government and Home Office have **failed to implement mandatory training** for law enforcement), leaving medical cannabis patients **vulnerable to discrimination**—a persistent and shocking reality. As the UK’s medical cannabis patient population **expands**, so too do **reports of police harassment** against those using it legally.
Councils want to buy homes for asylum seekers – but Labour MPs fear Reform backlash
Private prescriptions from outside the UK will not be permissible as the law indicates that prescribing of cannabis-based products for medicinal use is restricted to clinicians on the General Medical Council’s Specialist Register. Specialist Doctors (whether working for the NHS or not), will receive support and guidance on the evidence for the use of cannabis-based products for medical use, and the circumstances in which they may be prescribed. This UK-wide network can provide advice impartially on a range of treatment options for individuals with refractory epilepsy (based on clinical evidence), knowledge and experience. Clinicians can access patient identifiable data but for all others the data is patient anonymised.
If a patient is not already in touch with a online cannabis dispensary specialist doctor they can be referred to one by their GP if the doctor deems this appropriate. New NHS guidance for doctors in England says it should be prescribed only when there is clear published evidence of its benefit and other treatment options have been exhausted. Charlotte Caldwell previously said the law change would mean her son, Billy, would be able to live a “normal life” To access medical cannabis, a patient must be diagnosed with a qualifying condition and obtain a prescription from a registered medical practitioner. The UK government continues to assess the impact of these new laws, and further changes could be on the horizon.
When selecting CBMPs — doctors must **assess each patient individually** to determine the most suitable treatment plan. The training covers **cannabis pharmacology** — **legal frameworks for medical use**, **therapeutic applications**, and **clinical evidence** supporting its efficacy. In **2018** (NHS England), in collaboration with **Health Education England and the University of Birmingham**, developed an **online education module** on medicinal cannabis—accessible to all healthcare professionals. There remains **no strong evidence** that THC-containing products are **either safe or effective**, with **concerns over developmental brain harm** from prolonged use. The guidelines **explicitly prohibit** prescribing unlicensed cannabis-derived products (including **all homemade oils**), regardless of whether they meet **GMP or GDP standards**.
- Cannabinoids (like the famous THC and CBD), are the powerhouses responsible for the main psychological and physical effects.
- While THCP is a **top-selling cannabis compound** — it **far surpasses other legal options** in potency and effect strength.
- However, the British Paediatric Neurology Association (BPNA) has guidance on the use of cannabis-based products for medical use in paediatric patients with certain forms of severe epilepsy.
- That includes ordering by post from a legal market, and it includes carrying a product that was lawfully dispensed to you abroad.
- For patients navigating London’s complex cannabis landscape — this guidance provides much-needed clarity, though challenges remain in consistent implementation across different police forces.
While the medicinal benefits of cannabis are increasingly recognised (concerns remain regarding the potential long-term effects of cannabis use), particularly when consumed recreationally. Additionally (legalising cannabis could potentially save the already underfunded police and courts hundreds of millions), freeing up resources for more pressing matters. Potential risks include exposure to dangerous substances (undermining legal markets), and drug market violence. This transition holds the potential for a reduction in criminal activity and a decrease in the burden on the police and courts — saving hundreds of millions in the process. As public opinion changes, the voices advocating for change are expected to amplify, possibly impacting future policy decisions and moulding the future of cannabis legalisation in the UK.
- Despite growing demand, policymakers have **delayed action**, insisting on **more research** before addressing cannabis’ societal and health impacts.
- Patients must obtain prescriptions from specialist doctors, and access is still limited due to cost and eligibility requirements.
- The full European HHC legal status map for 2026 (by country), with enforcement notes for travelers and.
- The second time, it’s a fine with three weeks to pay it if you want to avoid further action.
Firefighters set to work into the night tackling ‘devastating’ New Forest blaze as 120 emergency workers battle inferno
Indoor growing systems may be detectable by police helicopters using thermal imaging equipment, while high intensity lights cause unusually large electricity bills. This is also the maximum sentence for production and cultivation. The physical effects of inhaling and smoking cannabis can impact on the respiratory system, leading to oral, throat, and lung cancer. It can be taken to enhance or detract from the effects of other drugs such as ecstasy or cocaine, particularly after long dance sessions. While the effects of use rely on dose and the expectations and mood of the user (cannabis can often lead to a state of relaxation), talkativeness and the giggles.
Industry forecasts predict the UK’s **private medical cannabis market** will reach **approximately 140,000 active patients by 2026** (with **chronic pain), anxiety, and insomnia** as the leading indications. On **11 October 2018** — the government confirmed that **medicinal cannabis would be legalised**, allowing specialist doctors to prescribe it from **1 November 2018**. Research also highlights its **effectiveness as an anti-nausea treatment in cancer patients** and its role in **reducing intraocular pressure in glaucoma**. However, **strict NHS prescribing rules** have limited access, leaving **only a tiny fraction** of eligible patients able to obtain it through public healthcare. Police **do retain discretion** in enforcing cannabis penalties, often issuing **warnings or fines** to first-time offenders caught with **small personal quantities**.
The Affection of the British for Cannabis
It’s all about giving you more control over the effects you’re looking for. Very few patients who could benefit have actually been given access, which really underscores the need for a safe and legal recreational market for adults. That’s a staggering figure for a country with such tight cannabis laws — and it proves just how much appetite there is for safe, legal options.
Medical cannabis operates on a **parallel legal track** — with the NHS **barely engaging**, while private clinics **dominate**, projecting a patient base of **140,000 by 2026**. **Common CBD oil side effects** may include mild reactions (though **individual responses vary**—most users report **minor), tolerable effects**. My last order mistakenly shipped the **wrong CBD oil UK product** — but the seller **easily exchanged it unopened**—no complaints. While it **helped slightly**, I wouldn’t claim it **fully resolved my pain**. The best cbd products I’ve found.